None listed
Conditions
Interventions
Drug : This study is to compare the bleeding frequency of the 90 mg ticagrelor bid group and the 45 mg ticagrelor bid group after evaluating the degree of platelet inhibition in patients with acute co
Sponsors
Pusan National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Acute Coronary Syndrome Patients who have completed a successful cardiovascular perfusion procedure PRU <90 patients Patients who voluntarily signed a research agreement
Exclusion criteria
Exclusion criteria: 1. Patients unable to take ticagrelor (severe chronic obstructive pulmonary disease, history of cerebral hemorrhage) 2. Patients with multi-vascular disease and coronary artery bypass surgery 3. Moderate-Those with severe liver disease 4. Those who have bradycardia symptoms such as same-sex bradycardia and atrioventricular conduction block 5. Those with respiratory distress, such as those with chronic obstructive pulmonary disease. 6. Pregnant or lactating women 7. Those who have undergone hemodialysis or peritoneal dialysis due to end stage renal failure and have undergone kidney transplantation 8. A person who, due to other reasons, judges that participation in a clinical trial is inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BARC bleeding | — |
Secondary
| Measure | Time frame |
|---|---|
| platelet reactivity unit by VerifyNow;Borg Dyspnea scale;MACCE(CV death, MI, stroke), major bleeding | — |
Countries
Korea, Republic of
Contacts
Public ContactJinsup Park
Pusan National University Hospital
Outcome results
None listed